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1 Abstract
2 Inflammation is a major cause of chronic diseases. Several studies have investigated the effects
3 of soy intake on inflammatory biomarkers; however, the results are equivocal. The aim of this
4 study was to conduct a systematic review and meta-analysis of clinical trials that evaluated the
5 effect of soy consumption on inflammatory biomarkers. Medline, Scopus, ISI Web of Science,
6 and Google Scholar were systematically searched, up to and including May 2020, for clinical
7 trials that evaluated the effects of soy and soy products on tumor necrosis factor α (TNF-α),
8 Interleukin-6 (IL-6), Interleukin-2 (IL-2), Interleukin1-β (IL1-β), and Interferon gamma (IFN­
9 γ) in adults. A random-effects method was used to calculate overall effects, and subgroup
10 analyses were performed to discern probable sources of inter-study heterogeneity. A total of
11 28 clinical trials were included. Although soy consumption reduced TNF-α (Hedges’ g= −0.28; 
12 95%CI: −0.49, −0.07), it had no significant effect on IL-6 (Hedges’ g= 0.07, 95% CI: −0.14,
13 0.28), IL-2 (MD= −1.38 pg/ml; 95%CI: −3.07, 0.31), IL1-β (MD= −0.02 pg/ml; 95%CI: −0.08,
14 0.03), and IFN-γ (MD= 1685.82 pg/ml; 95%CI: −1604.86, 4976.50). Subgroup analysis
15 illustrated a reduction in TNF-α in in parallel designed studies, at dosages ≥100 mg of 
16 isoflavones, and in unhealthy subjects. The present study showed that high doses of isoflavones
17 in unhealthy subjects may yield beneficial effects on TNF-α.
18 Keywords: soy, inflammation, interleukin, tumor necrosis factor α, meta-analysis
19 Introduction:
20 Inflammation is a complex immune response to the pathogenic agents (1) . Indeed, both cell­
21 mediated and humoral responses are involved in inflammation (2); whilst reactive oxygen 
22 species are key molecules that play a major role in the initiation and progression of the
23 inflammatory response (3) .
       
 
      
         
     
      
        
    
         
         
       
        
     
   
     
         
     
         
         
   
        
            
       
       
      
24 Inflammation may be classified into two types: acute and chronic (4). Acute inflammation is a
25 short-term immune response to detrimental conditions, such as tissue injury, and can facilitate 
26 (5) repair, turnover, and adaptation of tissues . Although chronic inflammation has many
27 characteristics of acute inflammation; it is usually mild and permanent (6) . Although chronic
28 inflammation is not considered as a separate disease, several chronic diseases have an 
29 (4) (7) inflammation-based pathogenesis . Accumulating evidence suggests that diabetes , 
30 (8) (9) (10) (11) cardiovascular diseases , cancer , obesity , rheumatoid arthritis , and chronic
31 respiratory diseases (12) are all associated with inflammation.
32 Lifestyle modification, including adopting a healthy diet (13), regular exercise (14), adequate 
33 sleep (15), avoiding smoking (16) , and stress management (17) can reduce chronic inflammation.
34 Adequate intake of vegetables and legumes are regarded as an important part of a healthy diet
35 (18). Soybean is a legume, rich in health-promoting components such as vitamin E, vitamin C,
36 (19) folates, thiamin, riboflavin, amino acids, and bioactive compounds , whilst, to our
37 knowledge, soybean protein possesses antioxidant, anti-inflammatory, and anticancer
38 properties (20) . In addition to minerals, vitamins, fiber, and omega-3 fatty acids; soybean is
39 considered as a major source of phytoestrogens, particularly isoflavones (21; 22) . Genistein,
40 Daidzein, and Glycitein are the major isoflavones found in soybean (22). Genistein has anti­
41 inflammatory properties and is a strong inhibitor of tyrosine kinase enzyme (23), leading to, in
42 part, the suggestion that soybean intake may be efficacious in the prevention and treatment of
43 inflammation-based chronic diseases (21) .
44 Some studies have reported that soy consumption reduced some inflammatory biomarkers (24;
45 25); however, equivocally, soy intake had null (26; 27) or unfavorable (28) effects on inflammation
46 in other studies. Therefore, a systematic review and meta-analysis is needed to determine the 
47 overall effect of soy consumption on inflammatory biomarkers. Although a previous meta­
48 analysis reported that soy consumption had no significant effect on C-reactive protein (CRP)
      
         
   
  
  
       
         
     
  
  
        
     
            
         
         
          
         
          
    
  
    
      
  
49 (29), there is no comprehensive systematic review and meta-analysis of clinical trials that has
50 evaluated the impact of soy intake on other inflammatory markers. Therefore, the purpose of 
51 this systematic review and meta-analysis was to determine the effects of soy and soy products 
52 on inflammatory biomarkers.
53 Methods:
54 The present study was conducted according to the Preferred Reporting Items for Systematic
55 (30) Review and Meta-Analysis (PRISMA) . The study protocol was registered on an
56 international prospective register of systematic reviews (PROSPERO) (registration number:
57 CRD42020164481).
58 Search strategy
59 Electronic databases, including Medline, Scopus, ISI Web of Science and Google Scholar were
60 searched up to and including May 2020. Title, abstract, and keywords of articles were searched 
61 using the following keywords: ("soya" or "soy foods" or "soy milk" or "soybeans" or "soybean
62 protein" or " soy" or "isoflavones" or "phytoestrogens" or " genistein" or "genestein" or
63 "glycitein" or " daidzein" or " isolated soy protein" or " textured soy protein") AND 
64 ("interleukin-6 " or "IL-6" or "tumor necrosis factor-α" or" TNF-α" or "interleukin" or "
65 interleukin-8" or " inflammation" or "cytokine" or "IL-1β" or "IL-2" or " IL-4" or "IL-8" or
66 "IL-10" or "IFN-γ" or "inflammatory"). The references of the retrieved articles were also
67 searched manually. The search strategy was conducted without any restrictions.
68 Eligibility criteria
69 Two independent investigators (M.R and F.M) screened title, abstract, and full texts of included 
70 articles. All interventions that investigated the effects of soy and soy products on inflammatory
71 biomarkers including tumor necrosis factor α (TNF-α), interleukin-6 (IL-6), interleukin-2 (IL­
        
      
     
     
     
   
  
       
       
          
   
   
      
      
  
        
     
    
   
       
      
          
      
72 2), interleukin1-β (IL1-β) or interferon gamma (IFN-γ), in healthy and unhealthy adults, were
73 included. Articles were excluded if they: 1) were in vitro or animal-based studies; 2) were
74 editorials, letters, review articles, or meeting abstracts; 3) were short-term (<1 week); 4) used 
75 soy in combination with other foods or adjunct interventions; 5) had no control group; 6) did
76 not report dose of soy or isoflavone in intervention group; 7) reported post-exercise
77 inflammation; 8) included pregnant women, or children, and 9) had insufficient reported data.
78 Data extraction
79 The following information was extracted from each eligible article: the first author's name and
80 year of publication; sample size; age of participants; design of clinical trial and 
81 duration; dosage and type of soy or soy product used in the intervention group; details 
82 regarding intervention in control group, and characteristics of subjects. IL-6, TNF-α, IL-2, IL­
83 10, IL-1β, and IFN-γ were considered as main outcomes. Mean and standard deviation (SD) or 
84 standard error (SE) for outcomes were extracted. CRP was not entered in the present study
85 because a previous meta-analysis reported the effect of soy consumption on CRP (29) .
86 Assessment of quality
87 The quality of studies was assessed according to the Cochrane Risk of Bias Tool (31). Two
88 authors (M.R. and F.M.) independently evaluated the quality of eligible studies through
89 Cochrane Risk of Bias tool including seven domains: 1) random sequence generation (selection 
90 bias), 2) allocation concealment (selection bias), 3) blinding of participants and personnel 
91 (performance bias), 4) blinding of outcome assessment (detection bias), 5) incomplete outcome
92 data (attrition bias), 6) selective reporting (reporting bias), and 7) other sources of bias. Each 
93 domain was classified into three classes: low risk (one plus (+) sign), high risk (one negative
94 (-) sign), and unclear risk of bias (question mark (?)). Therefore, the overall quality of each 
       
  
  
       
     
      
         
         
    
     
       
          
  
   
       
     




      
     
     
95 study was considered as good (low risk for more than two domains), fair (low risk for two 
96 domains), or weak (low risk for less than two domains), respectively.
97 Statistical analysis
98 This meta-analysis was conducted using STATA software (version 11, Stata Corporation). A
99 limited number of studies reported net change; thus, to calculate effect size in studies that net 
100 change was not reported in the soy and control group, we used mean±SD/SE or median and 
101 IQR (32; 33) . To compute the overall effect, we converted SE to SD. TNF-α and IL-6 were
102 reported in different units through the studies; therefore, Hedges’ g was used for these
103 variables. In contrast, mean difference was applied for IL-1β, IL-2, and IFN-γ. A random ­
104 effects model was conducted to calculate pooled effect size for each main outcome. I squared
105 (𝐼2) and a fixed-effect model were used to evaluate inter-study and between-subgroup
106 heterogeneity, respectively. A pre-planned subgroup analysis based on soy type, soy dosage,
107 duration of intervention, design of the study, gender, age, and health status was performed to 
108 discern potential sources of inter-study heterogeneity.
109 To evaluate the possible influence of each study on the pooled effect size, the stability of the
110 results was checked using sensitivity analyses. Egger's regression asymmetry test and Begg's
111 rank-correlation method were conducted to assess publication bias. A P-value <0.05 was
112 considered to represent statistical significance.
113 Results
114 Systematic review
115 Details regarding study selection process are illustrated in Figure 1. A total of 15179 records 
116 were identified through database searching. Subsequently, 3913 duplicate records were
117 removed, and 11266 records were screened. After screening, 11218 records were excluded, and 
      
      
        
       
    
                              
       
      
   
      
                         
                   
                     
                   
          
     
    
    
       
                         
   
  
        
         
       
118 of the 48 articles that remained for full-text assessment, 19 articles were excluded due to being
119 short term (<1 week) trials (n=3), using soy in combination with other intervention (n=5), using
120 gene expression and cell cultures (n=2), reporting limited data regarding amount of pure soy
121 or isoflavones (n=1), reporting post-exercise inflammation (n=1), being meeting abstract (n=1),
122 and having no control group (n=6). Finally, 29 articles were included in qualitative synthesis
123 (24; 25; 26; 27; 28; 34; 35; 36; 37; 38; 39; 40; 41; 42; 43; 44; 45; 46; 47; 48; 49; 50; 51; 52; 53; 54; 55; 56; 57) . Whilst, of 29
124 publications eligible for systematic review, one study was not included in meta-analysis
125 because it did not report applicable data for quantitative analysis, resulting in 28 articles entered 
126 into the meta-analysis (57) .
127 The result of quality assessment of included articles is shown in Table 1. Of 28 included
128 studies, 25 articles were randomized (24; 25; 26; 27; 28; 34; 36; 37; 38; 39; 42; 43; 44; 45; 46; 47; 48; 49; 50; 51; 52; 53;
129 54; 55; 56) , and only 16 articles reported randomization methods (24; 25; 26; 27; 28; 34; 36; 37; 38; 39; 44; 45;
130 46; 48; 50; 56). Fifteen studies were double-blinded (24; 25; 26; 27; 28; 36; 37; 38; 39; 40; 44; 45; 46; 47; 56) , and 13
131 trials had no report regarding blinding procedure (34; 35; 41; 42; 43; 48; 49; 50; 51; 52; 53; 54; 55) . Only five
132 articles reported reasons for participant withdrawal (35; 40; 41; 47; 49). Of the 28 included studies in
133 the meta-analysis, the quality of all articles was high, except for 2 studies which were ranked 
134 as low (35; 41) .
135 Details of all 28 articles are presented in Table 2. Twenty-eight clinical trials that enrolled a
136 total of 1816 participants (mean age=51.4 y) were included in this meta-analysis (24; 25; 26; 27; 28;
137 34; 35; 36; 37; 38; 39; 40; 41; 42; 43; 44; 45; 46; 47; 48; 49; 50; 51; 52; 53; 54; 55; 56). Unhealthy participants had prostate
138 cancer, metabolic syndrome, irritable bowel syndrome, hypercholesterolemia, rheumatoid
139 arthritis, climacteric syndrome, Hashimoto's thyroiditis, poorly controlled asthma, non­
140 alcoholic fatty liver disease, and hypertension. Soy was used in different forms through the
141 studies, including soy milk, soy protein, soy nut, and isoflavones. The range of dosage of 
142 Isoflavones was 40 to 600 mg, whilst the duration of study varied from 4 to 96 weeks. Twenty
       
            
       
    
  
  
    
         
     
        
  
  
        
    
     
     
        
      
     
       
       
      
     
       
143 studies used a parallel design and eight studies used a crossover design. The most reported 
144 outcomes were TNF-α (n=22) or IL-6 (n=21), whilst IL-1β and IL-2 were measured in three
145 studies, and IFN-γ level was measured in two studies. IL-10 level was only reported in one
146 study, and therefore, it was only reported in the systematic review.
147 Meta-analysis
148 The effect of soy and soy products on IL-6
149 A meta-analysis of 21 clinical trials (23 effect sizes) did not yield any significant change in IL­
150 6 level following soy and soy products consumption (Hedges’ g: 0.07, 95% CI: −0.14, 0.28)
151 (Figure 2). There was significant heterogeneity between trials (I2=72%; P<0.001); however, 
152 we could not discern the sources of heterogeneity by using pre-planned subgroup analysis
153 (Table 3).
154 The effect of soy and soy products on TNF-α
155 The effect of soy intake on TNF-α level was evaluated in 22 studies (23 effect sizes). Pooled
156 analysis demonstrated a significant reduction in TNF-α in the soy group compared with 
157 controls (Hedges’ g: −0.28; 95% CI: −0.49, −0.07). A significant inter-study heterogeneity was 
158 identified (I2=82.4%; P<0.001), and pre-planned subgroup analysis by soy dosage, design of 
159 the study, health status, and soy type attenuated the heterogeneity (Figure 3). As shown in 
160 Figure 3A, a significant reduction in TNF-α was found in studies that used ≥100 mg of 
161 isoflavones (Hedges’ g: −0.47; 95% CI: −0.79, −0.14; I2 =58.1%). However, we did not observe
162 any significant effect at dosages <100 mg (Hedges’ g: −0.30; 95% CI: −0.73, 0.13; I2 = 89.4%; 
163 P for between subgroup heterogeneity=0.007). A significant decrease was shown in parallel 
164 designed clinical trials (Hedges’ g: −0.35; 95%CI: − 0.66, −0.03; I2 =84.6%); contrastingly, 
165 cross-over studies did not show any significant effect (Hedges’ g: −0.06; 95% CI: −0.24, 0.13;
166 I2 = 50.0%; P for between subgroup heterogeneity=0.001) (Figure 3B). Studies that included
      
        
     
        
    
       
      
  
  
    
     
      
  
  
    
    
  
   
     
   
      
  
  
167 unhealthy participants demonstrated a significant reduction in TNF-α (Hedges’ g: −0.56; 
168 95%CI: −0.97, − 0.14; I2=90.3%; P for between subgroup heterogeneity=0.005), whilst results
169 in “healthy”, “overweight or obese”, and “not reported” subgroups were not significant (Figure
170 3C). Subgroup analysis by soy type further indicated a significant reduction in TNF-α in the 
171 studies that used isoflavones supplements (Hedges’ g: −1.00; 95%CI: −1.94, −0.06; I2 =94.4%; 
172 P for between subgroup heterogeneity <0.001), whilst results in “soy milk”, “soy protein”, and 
173 “soy nut” subgroups were not significant (Figure 3D). Further subgroup analyses that could 
174 not explain heterogeneity are reported in Table 3.
175 The effect of soy and soy products on IL-2
176 Overall effect sizes of 3 clinical trials (3 effect sizes) did not show any significant impact of
177 soy consumption on IL-2 level (MD= −1.38 pg/ml; 95% CI: −3.07, 0.31). Although a high inter­
178 study heterogeneity was found (I2 = 99.6%; P<0.001), subgroup analysis was not applicable 
179 because of a limited number of studies.
180 The effect of soy and soy products on IL1-β
181 Pooled effect sizes of 3 trials (3 effect sizes) did not show any significant effect of soy
182 consumption on IL1-β (MD= −0.02 pg/ml; 95%CI: −0.08, 0.03). There was no heterogeneity
183 between studies (I2= 0.0%; P=0.447).
184 The effect of soy and soy products on IFN-γ
185 Overall effect sizes of 2 trials (2 effect sizes) did not show a significant effect of soy
186 consumption on IFN-γ level (MD= 1685.82 pg/ml; 95%CI: −1604.86, 4976.50). A high inter­
187 study heterogeneity was found (I2 = 99.8%; P<0.001), but subgroup analysis was not carried
188 out because of an insufficient number of studies.
189 Sensitivity analysis
         
       
      
   
  
     
     
     
  
       
    
        
      
      
      
     
         
      
        
      
        
    
        
190 To evaluate the influence of any individual study on the overall effect size, a sensitivity analysis
191 was Performed. For IL-6, TNF-α, IL-2, and IL-1β, excluding any of the studies did not
192 significantly alter the findings. Furthermore, because of the low number of articles, a sensitivity
193 analysis was not carried out for IFN-γ.
194 Publication bias 
195 Clinical trials did not show publication bias for IL-6 (P=0.39 for Begg's test; P=0.40 for Egger's 
196 test), TNF-α (P=0.27 for Begg's test; P=0.09 for Egger's test), IL-2 (P=0.11 for Begg's test; 
197 P=0.26 for Egger's test), and IL-1β (P=0.60 for Begg's test; P=0.14 for Egger's test).
198 Discussion
199 The key findings of this study were that that soy intake had no significant effect on IL-6, IL­
200 1β, IL-2 and IFN-γ, but did yield significant reductions in TNF-α. After conducting subgroup 
201 analysis, we found that the beneficial effect of soy intake on TNF-α was only evident in parallel 
202 designed studies, at dosages ≥100 mg of isoflavones, and in unhealthy subjects. However, the
203 lack of significant benefit of soy in cross-over studies and healthy subjects was likely due to
204 limited power, with only 6 studies for each subgroup. Indeed, the power of a meta-analysis
205 strongly depends on number of included studies (Turner). Chronic inflammation, colloquially
206 termed the “silent killer”, acts as a strong disease-promoting factor in a variety of disorders,
207 (58) including arteriosclerosis, obesity, and cancer . Although a review article previously
208 reported the effect of soy and soy product on CRP, there is no systematic review and meta­
209 analysis regarding other inflammatory markers such as TNF-α, IL-6, IL-1β, IL-2 and IFN-γ. A 
210 previous meta-analysis reported a non-significant reduction in serum hs-CRP following soy
211 products consumption (29), which is comparable to our results regarding IL-6, IL-1β, IL-2 and
212 IFN-γ. In contrast, however, we found that soy intake had a favorable effect on TNF-α. 
        
  
      
   
        
     
    
       
  
       
  
      
       
     
   
 
       
       
       
          
  
      
   
           
213 Therefore, it is possible that the effect of soy intake may not be comparable on all inflammatory
214 markers.
215 In this meta‐analysis of clinical trials, we found that soy and soy products consumption had no
216 significant effect on IL-6. However, calculated confidence interval (CI) for the effect of soy
217 nut consumption was very close to the significant increase threshold. Indeed, it may be due to
218 the fact that soy nut is usually consumed in roasted and salted forms. Also, the CI was very
219 close to statistical significance in IL-6 measured in crossover studies. Although crossover 
220 studies are more powerful in controlling confounding variables, the number of these studies 
221 was low compared with parallel designed studies. Nevertheless, although statistical 
222 significance was not formally attained, these results should not be simply overlooked and future
223 studies should further investigate the potential of soy on IL-6.
224 Our findings showed that, in contrast to “healthy” and “overweight or obese” subgroups, soy
225 intake had a significant effect on reducing TNF-α level in unhealthy subjects. Included studies 
226 in the “unhealthy” subgroup enrolled overweight, obese, or normal weight participants with
227 prostate cancer, metabolic syndrome, irritable bowel syndrome, hypercholesterolemia, 
228 rheumatoid arthritis, climacteric syndrome, Hashimoto's thyroiditis, asthma, non-alcoholic 
229 fatty liver disease, or hypertension. Studies in the “overweight and obese” subgroup recruited 
230 healthy, overweight, and obese subjects. A previous study showed that the pattern of
231 inflammation is different between healthy and unhealthy obese subjects (59), indicating that soy
232 intake may be effective against high levels of TNF-α, as observed in unhealthy, morbidly obese, 
233 patients.
234 We observed that parallel designed studies reported a significant effect of soy intake on TNF­
235 α level. In contrast, however, crossover studies showed no effect. Although cross-over studies 
236 are more precise in controlling for confounding variables, the number of these studies was low
      
   
       
      
       
       
     
    
         
       
     
   
    
    
         
       
    
   
       
   
     
    
        
    
237 (n=5) compared with parallel designed studies (n=17); highlighting that more cross-over 
238 studies should be undertaken in this regard. 
239 According to our findings, only soy isoflavones consumption yielded a reduction in TNF-α.
240 Isoflavones are major phytoestrogens in soy beans and structurally similar to 17-beta-estradiol
241 (60) . Genistein, daidzein, and glycitein were the types of soy isoflavones used in included
242 studies. The bioavailability of isoflavones is more than other flavonoids (61); indeed, Ganai et
243 al. reported that genistein reduced nitric oxide (NO) and prostaglandin E2 (PGE2), and 
244 suppressed production of d-galactosamine-induced proinflammatory cytokines including TNF­
245 α in Wistar rats (62). Moreover, a previous study, in a murine model, showed that daidzein
246 inhibits TNF-α-induced protein poly-adenosine diphosphate-ribosylation (63) . Tanaka et al.
247 illustrated that daidzein suppresses the Lipopolysaccharide (LPS)-induced TNF-α expression
248 (64) , whilst genistein can reportedly prevent insulin receptor substrate-1 (IRS-1) serine
249 phosphorylation through 5'-adenosine-monophosphate-activated protein kinase (AMPK) (65) . 
250 Indeed, AMPK activation has a substantial role in anti TNF-α property of genistein (65) . 
251 The beneficial effects of soy isoflavones may be related to equol,, a specific estrogenic
252 metabolite of daidzein produced by bacteria in the gut(66) . Indeed, some evidence suggests that
253 differences in equol production between humans (between racial/ethnic groups) may explain
254 the reported differences in beneficial effects (67) . In the present meta-analysis, the conversion
255 of isoflavones to equol was only measured in two studies(36; 37), therefore, we were unable to
256 include the conversion of isoflavones to equol in our analysis.
257 Although soy protein has some beneficial effects on health; high intake or prolonged
258 consumption of soy protein or raw soybean can be harmful to health. Indeed, soy protein an 
259 have adverse effects on the endocrine glands, liver, and kidney, and elicit carcinogenic effects
260 on the breast, pancreas, and thyroid gland (68) . Moreover, soy genistein can induce formation 
    
    
       
         
     
           
      
     
       
  
  
       
     
        
     
    
  
      




261 of mutagenesis and carcinogenesis, and proliferation of implanted human breast cancer cells 
262 (69) . Therefore, high consumption of soy and soy products should not be advocated.
263 The current meta-analysis has some strengths that should considered. The sample size was 
264 large, because we were able to include 28 articles (1816 participants). Both Egger's and Begg's
265 tests indicated no evidence for publication bias. Finally, a comprehensive, pre-defined,
266 subgroup analysis was run. Despite the aforementioned strengths, there are a number of
267 limitations that should be considered: 1) insufficient follow-up duration in some studies, and
268 2) the results of most included studies were not adjusted for confounding factors. However,
269 with regard to these three principle limitations, they were out of the operational control of the
270 study. 
271 Conclusion
272 In conclusion, the present systematic review and meta-analysis indicated that soy and soy
273 products consumption had no effect on inflammatory biomarkers; IL-6, IL-1β, IL-2, and IFN­
274 γ. A significant reduction was only observed on TNF-α in some specific subgroups. The authors 
275 advocate that further, well-controlled, studies should be conducted to clarify the safety and 
276 efficacy of soy intake on inflammatory biomarkers.
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Notes about subjects 




50 g/d soy protein 
(73 mg/d isoflavone) 
low-fat 
dairy food 








diets containing 25 g/d
soy protein 
(+90 mg/d isoflavones) 
































Healthy postmenopausal women 
postmenopausal women with the metabolic 
syndrome 
Maskarinec 20(20/0) 59 Crossover( 12 High-soya diet (69 mg low-soya diet(less IL-6 Healthy men 
(2008) No) weeks isoflavone per day) than 5 mg









TLC diet + soy nuts
(101 mg isoflavones) 
TLC diet IL-6 Healthy postmenopausal 
normotensive or hypertensive women 
Beavers(2009) United
States 




consume 3 servings of
























20 g soy protein (160
mg of total 
Isoflavones) 
soy milk diet (three
servings of calcium
fortified soy milk) 
20 g of whole milk
protein 
high milk diet 
(three servings of
low fat milk) 
TNF-α ,IL-6 
TNF-α,IL-6 
Healthy postmenopausal women 






























80mg of isoflavone ) 
Shake + 20 g soy 
protein (160 mg
isoflavones) 
20 g soy protein (160
mg Isoflavones) 
1200 kcal diet+ 
exercise 
Shake 





Healthy obese postmenopausal women 
Postmenopausal caucasian and african american
women 






































80mg of isoflavone ) 
soy isolate protein(18 g
soy protein, 6 g milk
protein) 
29 g/d soyabean 
(kinako) 




24 g of milk protein 
Usual diet 






Moderately hypercholesterolemic chinese adults 
Women with the metabolic syndrome 








40 g soybean protein
(89.3 mg isoflavones) 
40 g of milk protein 
supplement 
IL-6,TNF-α Adults in New Orleans, Louisiana and Jackson,
Mississippi 







Starch+ Vitamin D TNF-α ,IL-6 Chinese women suffering from climacteric 
syndrome 















98 mg isoflavone matching
placebo(less than
0.05mg isoflavone) 
IL-6 Poorly controlled asthma 



































   
    
   
 




      
   
 
    
  
   






    
   
   
   
 
   











      
 
   








      
  
 













        












   
 
   
 










             
Mohammad- Iran 25(0/25) 46 Crossover( 4 diet containing diet containing TNF-α,IL- Women with rheumatoid arthritis 


























20 g Soy milk powder
(2.0g free plant 
sterols) 
milk enriched with 2·8
g soya - phospholipids 
600 mg/d genistein 












Overweight or obese men 









15 g soy protein (50
mg isoflavones) 
Control  diet IL-6,TNF-α Healthy postmenopausal women 




250 mg genistein Cornstarch IL-6,TNF-α Non-alcoholic fatty liver disease 
Giolo(2018) Brazil 32(0/32) 60 Parallel(Ye 10 100 mg isoflavones+ 100 mg of IL-6 Non-obese, postmenopausal women 
s) weeks exercise training cornstarch+ 
exercise training 
Iran 46(0/46) 41 Parallel(Ye 6 40 mg/d soy isoflavones Corn starch TNF-α Female patients with irritable bowel syndrome 
Jalili(2019) s) weeks 
Table 2. Characteristics of included clinical trials in meta-analysis.




















































     
     
     
 
 
     
 
     
 
 
      
 




     
 
 










     
     




      
      





      
      
     
Subgroup Studie 
s (n)






male 4 0.14(-0.18,0.45) 15.1% 0.316 
Gender female 15 0.15(-0.08,0.39) 69.9% 0.000 <0.001 
both 2 0.02(-0.64,0.67) 0.0% 0.989 






















































soy milk 4 -0.02(-0.39,0.34) 25.8% 0.257 
soy nut 4 0.27(-0.02,0.55) 0.0% 0.437 
<100 8 0.19(-0.09,0.47) 46.6% 0.070 
Dose(mg) ≥100 8 -0.07(-0.58,0.44) 88.3% 0.000 0.808 
NR 7 0.07(-0.11,0.25) 0.0% 0.513 












       




































     
      




     






     




      
 
 










     
     




      
      






      
      
     




3 0.14(-0.19,0.48) 0.0% 0.563 
male 2 -0.07(-0.50,0.37) 0.0% 0.483 
Gender female 16 -0.32(-0.63,-0.02) 85.7% 0.000 0.961 
both 3 -0.11 (-0.44,0.22) 25.1% 0.263 















































soy milk 5 -0.39(-0.90,0.11) 63.7% 0.026 
soy nut 3 0.18(-0.16,0.52) 20.0% 0.287 
<100 10 -0.30(-0.73,0.13) 89.4% 0.000 
Dose(mg) ≥100 5 -0.47(-0.79,-0.14) 58.1% 0.049 0.007 
NR 8 -0.15 (-0.45,0.15) 66.4% 0.004 
healthy 5 -0.28(-0.56,0.01) 27.3% 0.240 
Subject unhealthy 11 -0.56(-0.97,-0.14) 90.3% 0.000 
NR 3 -0.04(-0.17,0.09) 0.0% 0.494 0.005 
overweigh 
t or obese
4 0.25(-0.02,0.52) 0.0% 0.552 
Table 3. Result of subgroup analysis of included studies in meta-analysis 
 
